table of contents table of contents

The objective of this study was to identify the molecular processes responsible …

Home » Biology Articles » Immunobiology » Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream » References

- Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream

1.   Callen JP, Bickers DR, Moy RL: Actinic keratosis.J Am Acad Dermatol 1997, 36:650-653.       2.   Schwartz RA: The actinic keratosis: a perspective and update.Dermatol Surg 1997, 23:1009-1019.       3.   Marks R, Rennie G, Selwood T: The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratosis.Arch Dermatol 1988, 124:1039-1042.       4.   Nghiem DX, Kazimi N, Mitchell DL, Vink AA, Ananthaswamy HN, Kripke ML, Ullric : Mechanisms underlying the suppression of established immune responses by ultraviolet radiation.J Invest Dermatol 2002, 119:600-608.       5.   Yantsos VA, Conrad N, Zabawski E, Cockerell CJ: Incipient intraepidermal cutaneous squamous cell carcinoma: A proposal for reclassifying and grading solar (actinic) keratosis.Semin Cutan Med Surg 1999, 18(1):3-14.       6.   Glogau RG: The risk of progression to invasive disease.J Am Acad Dermatol 2000, 42(1Pt2):23-24.       7.   Silapunt S, Goldberg LH, Alam M: Topical and light-based treatments for actinic keratosis.Semin Cutan Med Surg 2003, 22(3):162-170.       8.   Fu W, Cockerell CJ: The actinic (solar) keratosis: a 21st-century perspective.Arch Dermatol 2003, 139(1):66-70.       9.   Takeda K, Akira S: Microbial recognition by Toll-like receptors.J Dermatol Sci 2004, 34:73-82.       10.   Pasare C, Medzhitov R: t Toll-like receptors linking innate and adaptive immunity.Microbes Infect 2004, 6:1382-1387.       11.   Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.J Immunol 2002, 168(9):4531-4537.       12.   Kollisch G, Kalali BN, Voelcker V, Wallich R, Behrendt H, Ring J, Bauer S, Jakob T, Mempel M, Ollert M: Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes.Immunology 2005, 114(4):531-541.       13.   McInturff JE, Modlin RL, Kim J: The role of toll-like receptors in the pathogenesis and treatment of dermatological disease.J Invest Dermatol 2005, 125(1):1-8.       14.   Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.Nat Immunol 2002, 3:196-200.       15.   Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP: Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.Cell Immunol 2002, 218:74-86.       16.   Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens ML, Fox TL, Hougham AJ, Schmitt KA: Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.Antimicrob Agents Chemother 1998, 42(4):789-794.       17.   Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, Lee JH, Fox TL, Alomar A: Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology.J Am Acad Dermatol 2004, 51(4):547-555.       18.   Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, Owens M: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.J Am Acad Dermatol 2002, 47(3):390-8.       19.   Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R: Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.Arch Dermatol 2003, 139:1325-1332.       20.   Barnetson RStC, Stachell A, Zhuang L, Slade HB, Halliday GM: Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells.Clin Exp Dermatol 2004, 29:639-643.       21.   Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: A novel immune response modifier and a new class of drug.Int J Immunopharmacol 1999, 21:1-14.       22.   Lysa B, Tartler U, Wolf R, Arenberger P, Benninghoff B, Ruzicka T, Hengge UR, Walz M: Gene expression in actinic keratosis: Pharmacological modulation by imiquimod.Br J Dermatol 2004, 151(6):1150-1159.       23.   Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB: Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%.Antiviral Res 1999, 43:55-63.       24.   Bernstein DI, Miller RL, Harrison CJ: Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.J Infect Dis 1993, 167(3):731-735.       25.   Bernstein DI, Harrison CJ, Tepe ER, Shahwan A, Miller R: Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs.Vaccine 1995, 13(1):72-76.       26.   Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, Smith MH, Tomai MA: Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN.Cell Immunol 2000, 204:64-74.       27.   Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E: Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation.J Immunol 2003, 171(11):6275-6282.       28.   Affymetrix Inc: Gene chip expression analysis technical manual.2003.       29.   Schindler H, Wiese A, Auer J, Burtscher H: cRNA target preparation for microarrays: Comparison of gene expression profiles generated with different amplification procedures.Anal Biochem 2005, 344(1):92-101.       30.   Klur S, Toy K, Williams MP, Certa U: Evaluation of procedures for amplification of small-size samples for hybridization on microarrays.Genomics 2004, 83(3):508-517.       31.   Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, Medeiros LJ, Coombes KR: Validation of oligonucleotide microarray data using microfluidic low-density arrays: A new statistical method to normalize real-time RT-PCR data.Biotechniques 2005, 38(5):785-792.         32.   []       33.   Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, Narasimhan S, Kane DW, Reinhold WC, Lababidi S, Bussey KJ, Riss J, Barrett JC, Weinstein JN: GoMiner: a resource for biological interpretation of genomic and proteomic data.Genome Biol 2003, 4:R28.       34.   Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S: Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6.Nat Immunol 2004, 5(10):1061-8.       35.   Miettinen M, Sareneva T, Julkunen I, Matikainen S: IFNs activate toll-like receptor gene expression in viral infections.Genes Immun 2001, 2(6):349-355.       36.   Zarember KA, Godowski PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.J Immunol 2002, 168(2):554-561.     Erratum in: J Immunol 169(2):1136.   37.   Kokkinopoulos I, Jordan WJ, Ritter MA: Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes.Mol Immunol 2005, 42(8):957-968.       38.   Siren J, Pirhonen J, Julkunen I, Matikainen S: IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.J Immunol 2005, 174(4):1932-1937.       39.   Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, Matikainen S, Julkunen I: Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells.J Virol 2005, 79(15):9608-9617.       40.   Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T: The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.Nat Immunol 2004, 5(7):730-737.       41.   Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M Jr, Akira S, Yonehara S, Kato A, Fujita T: Shared and unique functions of the DExD/H-Box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity.J Immunol 2005, 175(5):2851-2858.       42.   Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S: IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.Nat Immunol 2005, 6(10):981-988.       43.   Taylor MW, Grosse WM, Schaley JE, Sanda C, Wu X, Chien SC, Smith F, Wu TG, Stephens M, Ferris MW, McClintick JN, Jerome RE, Edenberg HJ: Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro.J Interferon Cytokine Res 2004, 24(2):107-118.       44.   Nagorsen D, Deola S, Smith K, Wang E, Monsurro V, Zanovello P, Marincola FM, Panelli MC: Polarized monocyte response to cytokine stimulation.Genome Biol 2005, 6(2):R15.       45.   Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB: MDA-5 An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.Proc Natl Acad Sci USA 2002, 99(2):637-642.       46.   Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP: Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.J Immunol 2005, 174(3):1259-1268.       47.   Khabar KS, Al-Haj L, Al-Zoghaibi F, Marie M, Dhalla M, Polyak SJ, Williams BR: Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon.J Mol Biol 2004, 342(3):833-846.       48.   Der SD, Zhou A, Williams BR, Silverman RH: Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.Proc Natl Acad Sci USA 1998, 95(26):15623-15628.       49.   Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A, Yi T, Williams BR, Borden EC: Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: Greater potency of IFN-beta compared with IFN-alpha2.J Interferon Cytokine Res 2003, 23(12):745-756.       50.   Sarkar SN, Sen GC: Novel functions of proteins encoded by viral stress-inducible genes.Pharmacol Ther 2004, 103(3):245-259.       51.   Stroncek DF, Basil C, Nagorsen D, Deola S, Arico E, Smith K, Wang E, Marincola FM, Panelli MC: Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms.J Transl Med 2005, 3:24.       52.   Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D: Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein.J Virol 2001, 75:2684-2691.       53.   Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.Nature 2002, 418(6898):646-650.       54.   Chin KC, Cresswell P: Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus.Proc Natl Acad Sci U S A 2001, 98(26):15125-15130.       55.   Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, Hsu YT, Silverman RH, Youle RJ: The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis.Cell Death Differ 1998, (4):313-320.       56.   de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR: Functional classification of interferon-stimulated genes identified using microarrays.J Leukoc Biol 2001, 69:912-920.       57.   Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ: Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.Cancer Res 2004, 64(24):8973-8979.       58.   Keyser J, Schultz J, Ladell K, Elzaouk L, Heinzerling L, Pavlovic J, Moelling K: IP-10-encoding plasmid DNA therapy exhibits antitumor and antimetastatic efficiency.Exp Dermatol 2004, 13(6):380.       59.   Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A, Bhardwaj A: Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA.Mol Ther 2005, 11(1):112-119.       60.   Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR: Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector.Hepatology 2005, 42(3):702-710.       61.   Takaku T, Ohyashiki JH, Zhang Y, Ohyashiki K: Estimating immunoregulatory gene networks in human herpesvirus type 6-infected T cells.Biochem Biophys Res Commun 2005, 336(2):469-477.       62.   Kim EJ, Park JI, Nelkin BD: IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells.J Biol Chem 2005, 280(6):4913-4920.       63.   Ludlow LE, Johnstone RW, Clarke CJ: The HIN-200 family: More than interferon-inducible genes?Exp Cell Res 2005, 308(1):1-17.       64.   Chen GG, Lai PB, Ho RL, Chan PK, Xu H, Wong J, Lau WY: Reduction of double-stranded RNA-activated protein kinase in hepatocellular carcinoma associated with hepatitis B virus.J Med Virol 2004, 73(2):187-194.       65.   Keefe D, Shi L, Feske S, Massol R, Navarro F, Kirchhausen T, Lieberman J: Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis.Immunity 2005, 23(3):249-262.       66.   Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T: Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.J Cutan Pathol 2005, 32(4):257-262.       67.   Urosevic M, Oberholzer PA, Maier T, Hafner J, Laine E, Slade H, Benninghoff B, Burg G, Dummer R: Imiquimod treatment induces expression of opioid growth factor receptor: A novel tumor antigen induced by interferon-alpha?Clin Cancer Res 2004, 10(15):4959-4970.       68.   Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, Lee JH: Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, placebo-controlled trials.Arch Dermatol 2005, 141(4):467-473.       69.   Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Gilliet M: Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.J Natl Cancer Inst 2005, 97(15):1143-1153.       70.   Matsumoto M, Tanaka T, Kaisho T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA, Akira S: A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages.J Immunol 1999, 163:5039-5048.       71.   Walker MG: Z39Ig is co-expressed with activated macrophage genes.Biochim Biophys Acta 2002, 1574(3):387-390.       72.   Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB, Halliday GM: Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.Br J Dermatol 2006, 154:72-78.       73.   Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR: Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.Br J Dermatol 2004, 151(4):903-906.       74.   Wolf IH, Cerroni L, Kodama K, Kerl H: Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.Arch Dermatol 2005, 141(4):510-514.       75.   Bates EE, Fournier N, Garcia E, Valladeau J, Durand I, Pin JJ, Zurawski SM, Patel S, Abrams JS, Lebecque S, Garrone P, Saeland S: APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif.J Immunol 1999, 163(4):1973-1983.       76.   Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB, Zenke M: Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation.Gene 2004, 331:159-164.       77.   Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint Vis B, Briere F, Bates EE: Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells.Blood 2002, 100:3295-3303.       78.   Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M: Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod.J Immunol 2004, 173(5):3051-3061.       79.   Peiser M, Grutzkau A, Wanner R, Kolde G: CD1a and CD1c cell sorting yields a homogeneous population of immature human Langerhans cells.J Immunol Methods 2003, 279(1–2):41-53.       80.   Darmochwal-Kolarz D, Rolinski J, Buczkowski J, Tabarkiewicz J, Leszczynska-Gorzelak B, Zych I, Oleszczuk J: CD1c(+) immature myeloid dendritic cells are predominant in cord blood of healthy neonates.Immunol Lett 2004, 91(1):71-74.       81.   Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, Miller RL, Sauder DN: Imiquimod, a topical immune response modifer, induces migration of Langerhans cells.J Investig Dermatol 2000, 114:135-141.       82.   Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.Blood 2004, 103(8):3065-3072.       83.   Pisegna S, Zingoni A, Pirozzi G, Cinque B, Cifone MG, Morrone S, Piccoli M, Frati L, Palmieri G, Santoni A: Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells.J Immunol 2002, 169:68-74.       84.   Barber DF, Faure M, Long EO: LFA-1 contributes an early signal for NK cell cytotoxicity.J Immunol 2004, 173(6):3653-3659.       85.   Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y: Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes.Proc Natl Acad Sci USA 2005, 102(18):6437-6442.         86.   Cella M, Fujikawa K, Tassi I, Kim S, Latinis K, Nishi S, Yokoyama W, Colonna M, Swat W: Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity.J Exp Med 2004, 200(6):817-823.       87.   Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells.Nat Immunol 2001, 2(3):255-260.       88.   Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, Miyagi T, Suzuki T, Sasaki Y, Hayashi NT: Critical role of MHC class I-related chain A and B expression on IFNAα-stimulated dendritic cells in NK cell activation: Impairment in chronic hepatitis C virus infection.J Immunol 2003, 170:1249-56.       89.   Waterhouse NJ, Clarke CJ, Sedelies KA, Teng MW, Trapani JA: Cytotoxic lymphocytes; Instigators of dramatic target cell death.Biochem Pharmacol 2004, 68(6):1033-1040.       90.   Wowk ME, Trapani JA: Cytotoxic activity of the lymphocyte toxin granzyme B.Microbes Infect 2004, 6(8):752-758.       91.   Medley QG, Kedersha N, O'Brien S, Tian Q, Schlossman SF, Streuli M, Anderson P: Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition.Proc Natl Acad Sci U S A 1996, 93(2):685-689.       92.   Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA, Hayakawa Y: Activation of NK cell cytotoxicity.Mol Immunol 2005, 42:501-510.       93.   Ashton-Rickardt PG: The granule pathway of programmed cell death.Crit Rev Immunol 2005, 25(3):161-182.       94.   Denny MF, Patai B, Straus DB: Differential T-cell antigen receptor signaling mediated by the Src family kinases Lck and Fyn.Mol Cell Biol 2000, 20(4):1426-1435.       95.   Kuhne MR, Lin J, Yablonski D, Mollenauer MN, Ehrlich LI, Huppa J, Davis MM, Weiss A: Linker for activation of T cells, zeta-associated protein-70, and Src homology 2 domain-containing leukocyte protein-76 are required for TCR-induced microtubule-organizing center polarization.J Immunol 2003, 171:860-866.       96.   Wherry EJ, Ahmed R: Memory CD8 T-cell differentiation during viral infection.J Virol 2004, 78(11):5535-5545.       97.   Fuller MJ, Hildeman DA, Sabbaj S, Gaddis DE, Tebo AE, Shang L, Goepfert PA, Zajac AJ: Cutting edge: Emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help.J Immunol 2005, 174(10):5926-5930.       98.   Rodriguez MW, Paquet AC, Yang YH, Erle DJ: Differential gene expression by integrin beta 7+ and beta 7-memory T helper cells.BMC Immunol 2004, 5:13.       99.   Smith KJ, Hamza S, Skelton H: Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern.Clin Exp Dermatol 2004, 29(5):505-512.       100.   Bernstein DI, Harrison CJ, Tomai MA, Miller RL: Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.J Infect Dis 2001, 183(6):844-849.       101.   Stockfleth E, Christophers E, Benninghoff B, Sterry W: Low incidence of new actinic keratosis after topical 5% imiquimod cream treatment: A long-term follow-up study.Arch Dermatol 2004, 140(12):1542.       102.   Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B: IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities.J Immunol 2003, 171(7):3385-3393. [PubMed Abstract]

rating: 2.00 from 1 votes | updated on: 8 Aug 2007 | views: 9451 |

Rate article: